Anemia, a prevalent health concern globally, arises from low hemoglobin levels, often resulting in debilitating symptoms such as fatigue, hair loss, shortness of breath and poor appetite.

The sNDA is supported by data from the phase 3 ENERGIZE and ENERGIZE-T studies, which evaluated mitapivat vs placebo in patients with NTD and TD alpha- or beta-thalassemia, respectively.